Y
Yoshiyuki Wada
Publications - 11
Citations - 884
Yoshiyuki Wada is an academic researcher. The author has contributed to research in topics: Ramucirumab & Population. The author has an hindex of 7, co-authored 11 publications receiving 431 citations.
Papers
More filters
Journal ArticleDOI
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Masatoshi Kudo,Kazuomi Ueshima,Masafumi Ikeda,Takuji Torimura,Nobukazu Tanabe,Hiroshi Aikata,Namiki Izumi,Takahiro Yamasaki,Shunsuke Nojiri,Keisuke Hino,Hidetaka Tsumura,Teiji Kuzuya,Norio Isoda,Kohichiroh Yasui,Hajime Aino,Akio Ido,Naoto Kawabe,Kazuhiko Nakao,Yoshiyuki Wada,Osamu Yokosuka,Kenichi Yoshimura,Takuji Okusaka,Junji Furuse,Norihiro Kokudo,Kiwamu Okita,Philip J. Johnson,Yasuaki Arai +26 more
TL;DR: TACE plus sorafenib significantly improved PFS over TACE alone in patients with unresectable HCC, and Adverse events were consistent with those of previous TACE combination trials.
Journal ArticleDOI
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Masatoshi Kudo,Kazuomi Ueshima,S.L. Chan,Tomohiro Minami,Hirokazu Chishina,Tomoko Aoki,Masahiro Takita,Satoru Hagiwara,Yasunori Minami,Hiroshi Ida,Mamoru Takenaka,Toshiharu Sakurai,Tomohiro Watanabe,Masahiro Morita,Chikara Ogawa,Yoshiyuki Wada,Masafumi Ikeda,Hiroshi Ishii,Namiki Izumi,Naoshi Nishida +19 more
TL;DR: In patients with large or multinodular intermediate-stage HCC exceeding the up-to-seven criteria with Child–Pugh A liver function, lenvatinib provides a more favorable outcome than TACE.
Journal ArticleDOI
REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
Tatsuya Yamashita,Masatoshi Kudo,Kenji Ikeda,Namiki Izumi,Ryosuke Tateishi,Masafumi Ikeda,Hiroshi Aikata,Yasunori Kawaguchi,Yoshiyuki Wada,Kazushi Numata,Yoshitaka Inaba,Ryoko Kuromatsu,Masahiro Kobayashi,Takuji Okusaka,Toshiyuki Tamai,Chifumi Kitamura,Kenichi Saito,Katsuya Haruna,Kiwamu Okita,Hiromitsu Kumada +19 more
TL;DR: The efficacy and safety of LEN in the Japanese population were similar to those in the overall population of REFLECT, and with manageable adverse events, LEN is a new treatment option for Japanese patients with uHCC.
Journal ArticleDOI
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma analysis of REACH trial results by child-pugh score
Andrew X. Zhu,Ari David Baron,Peter Malfertheiner,Masatoshi Kudo,Seiji Kawazoe,Denis Pezet,Florian Weissinger,Giovanni Brandi,Carlo Barone,Takuji Okusaka,Yoshiyuki Wada,Joon Oh Park,Baek Yeol Ryoo,Jae Yong Cho,Hyun Cheol Chung,Chung Pin Li,Chia Jui Yen,Kuan Der Lee,Shao Chun Chang,Ling Yang,Paolo Abada,Ian Chau +21 more
TL;DR: Results from the REACH trial support the ongoing REACH-2 study of ramucirumab in patients with advanced HCC with underlying Child-Pugh A cirrhosis and baseline &agr;FP levels of 400 ng/mL or more.
Journal ArticleDOI
First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
Masatoshi Kudo,Kenta Motomura,Yoshiyuki Wada,Yoshitaka Inaba,Yasunari Sakamoto,Masayuki Kurosaki,Yoshiko Umeyama,Yoichi Kamei,Junichiro Yoshimitsu,Yosuke Fujii,Mana Aizawa,Paul B. Robbins,Junji Furuse +12 more
TL;DR: This data indicates that combination of an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for treatment of advanced/metastatic hepatocellul...